Startups

How Pipeline Organics Aims to Cut Wastewater Treatment Costs

Led by co-founders Andrew Raslan and Keyvan Jodeiri, Pipeline Organics is developing microbial fuel cells to help food and beverage manufacturers treat wastewater and recover energy as electricity.

Updated

November 16, 2026 12:32 PM

Concept visualisation of Pipeline Organics’ planned TankArc wastewater treatment and energy recovery system at a brewery. IMAGE: PIPELINE ORGANICS

A glass of beer or a bottle of soft drink leaves plenty behind before it reaches the shelf. Producing it requires water and electricity, then creates wastewater that manufacturers must pay to treat. For breweries and other food and beverage manufacturers working with tight margins, those bills can leave less money for new equipment, products and people.  

Pipeline Organics, led by Andrew Raslan (commercial) and Dr Keyvan Jodeiri (technology), sees a resource in that waste. The Nottingham-based cleantech startup, Pipeline Organics, is developing microbial fuel cells that treat food and beverage wastewater while generating electricity. The aim is to help factories lower their operating costs by recovering value from a stream they already produce every day.

Founded in August 2021, Pipeline Organics grew out of the University of Nottingham’s Young Entrepreneurs Scheme, YES20. The founding team won its Engineering, Energy and Environment stream before establishing the company. Andrew, now CEO, brought a background in molecular microbiology and antimicrobial research, later moving into project management and commercialization.

Co-founder and chief scientific officer Keyvan Jodeiri brought a different piece of the puzzle. His research explored biofuel cells that could use sugars in blood to generate electricity for medical implants. The team began asking whether related principles could work outside the body, using organic material in industrial wastewater as fuel. Turning that idea into a business meant finding an application where the environmental benefits came with a clear financial incentive.

Food and beverage manufacturing offered that opportunity. Breweries and other food and beverage manufacturers produce wastewater rich in biodegradable organic material such as leftover carbs and fats or dead proteins, making it suitable food for microorganisms. Treating it at the factory also gives the company a more predictable waste stream than the mixture arriving at a general sewage treatment plant.

“What is filthy for you as a manufacturer is food for the bacteria,” Andrew explains.

‍

Illustration of Pipeline Organics’ planned system, using microbial fuel cells to treat industrial wastewater and generate electricity. IMAGE: PIPELINE ORGANICS

‍

The company’s system, TankArc, contains reactors with specially designed, 3D-printed lattices. Microorganisms growing on the anode break down organic material in wastewater, releasing electrons that electrodes capture as electrical current. This reduces the organic pollution load while recovering some of its energy. Reactors can be grouped into racks or, eventually, containers equipped with plumbing, batteries and controls to serve different factory sizes.

Andrew describes the system as being designed to become self-powering, provided its electricity output scales as expected, with surplus energy available for use on site. At the moment, replacing a brewery’s entire electricity supply is beyond the immediate promise, Andrew admits. The more practical proposition is reducing the amount of power a manufacturer needs to buy through site efficiency upgrades, while cutting its wastewater treatment burden.

The treated wastewater would then go into the sewer for further treatment. Since it contains fewer pollutants, manufacturers could pay less in treatment charges or, in some cases, avoid them altogether. Pipeline Organics is also exploring ways to take the process further by working with partners to make water reuse possible. This could allow manufacturers to reuse the treated water for tasks that do not require high-purity water, such as post-production washing, which accounts for a large share of fresh-water use in the industry.

Much of TankArc’s engineering sits in the lattice itself. It needs sufficient surface area for the biological process while allowing wastewater to flow through without clogging. Different waste streams require different designs. Pipeline Organics combines engineering calculations with proprietary AI-assisted algorithms to adapt the geometry for applications such as beer, wine or fruit juice production.

‍

5-litre microbial fuel cell developed by Pipeline Organics. IMAGE: PIPELINE ORGANICS

‍

Andrew sees this design process as a competitive advantage. Once the geometry has been developed, components can be manufactured from the resulting 3D models. The difficult part is knowing how to design a cell that performs in a particular environment.

The company is competing with established wastewater treatment and energy recovery methods. Anaerobic digestion, for example, produces biogas that can subsequently generate heat and electricity. Pipeline Organics is pursuing direct electricity recovery through compact, modular equipment. Its suitability will depend on the site, the wastewater and the savings it can deliver.  

Early brewery trials have helped the team test those assumptions. At Little Ox Brewery, Pipeline Organics used a compact four-reactor system with real wastewater to assess compatibility and electrical output. The trial also provided practical lessons about monitoring, handling and operating equipment around a working production site. The company is working with Castle Rock Brewery in Nottingham as another development partner and have achieved onsite results that are close to commercial readiness.  

These demonstrations represent an early step towards industrial deployment. During our interview, Andrew said Pipeline Organics had begun selling paid feasibility pilots that measure performance using customers’ wastewater under actual operating conditions. Larger reactor racks would be at the next stage, followed by containerised systems for facilities producing much greater volumes of effluent. They expect to deploy full-scale containers in 2027.

Scaling brings another set of challenges. The team is developing repeatable methods for producing conductive electrodes, maintaining wastewater flow and assembling larger systems. Reducing manufacturing costs while maintaining treatment performance is a central part of this work.

‍

Pipeline Organics’ current benchtop prototype of its microbial fuel cell system. IMAGE: PIPELINE ORGANICS

‍

There will also be useful discoveries along the way: Chief Scientific Officer Keyvan says longer-term ambitions include developing the technology for wastewater sensing and exploring how recovered electricity could support electrochemical production of higher-value chemicals. These could open additional applications for the platform, while the immediate priority remains manufacturing and scaling the wastewater treatment system.

The proposed leasing model reflects the focus on customer economics. Manufacturers would rent equipment rather than purchase it upfront, retaining part of the savings after paying Pipeline Organics. Making that arrangement attractive requires dependable treatment, manageable maintenance and savings that hold up over time.  

Andrew’s and Keyvan’s longer-term vision includes a wider portfolio of environmental technologies. For now, the next test is closer to the brewery floor: can the company turn promising small reactors into equipment food and beverage manufacturers can rely on?

“One man’s waste is another man’s raw material if you’re smart about it,” Andrew says. Pipeline Organics is building its business around that possibility, starting with the water left behind by a drink.

Keep Reading

Hong Kong

Hong Kong AI Biotech Startup METiS TechBio Draws Major Investor Demand in IPO

METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body

Updated

August 10, 2026 5:56 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH

Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.

The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.

Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.

The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.

That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.

METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.

The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.

One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.

Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.

METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.

The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.

Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."

The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.

For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.